IP Verse

C7-Fluoro Substituted Tetracycline Compounds - EP3000805

The patent EP3000805 was granted to Tetraphase Pharmaceuticals on Oct 18, 2017. The application was originally filed on Aug 7, 2009 under application number EP15180611A. The patent is currently recorded with a legal status of "Revoked".

EP3000805

TETRAPHASE PHARMACEUTICALS
Application Number
EP15180611A
Filing Date
Aug 7, 2009
Status
Revoked
Jul 9, 2021
Grant Date
Oct 18, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJul 18, 2018LAMPINGADMISSIBLE

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS3304227
DESCRIPTIONUS4666897
DESCRIPTIONUS4704383
DESCRIPTIONUS4925833
DESCRIPTIONUS4935412
DESCRIPTIONUS5231017
DESCRIPTIONUS5258371
DESCRIPTIONUS5308839
DESCRIPTIONUS5321017
DESCRIPTIONUS5459135
DESCRIPTIONUS5523297
DESCRIPTIONUS5532227
DESCRIPTIONUS5668122
DESCRIPTIONUS5770588
DESCRIPTIONUS5773430
DESCRIPTIONUS5789395
DESCRIPTIONUS5827840
DESCRIPTIONUS5834449
DESCRIPTIONUS5834450
DESCRIPTIONUS5837696
DESCRIPTIONUS5843925
DESCRIPTIONUS5919774
DESCRIPTIONUS5919775
DESCRIPTIONUS5929055
DESCRIPTIONUS5977091
DESCRIPTIONUS5998390
DESCRIPTIONUS6015804
DESCRIPTIONUS6043225
DESCRIPTIONUS6043231
DESCRIPTIONUS6100248
DESCRIPTIONUS6231894
DESCRIPTIONUS6277061
DESCRIPTIONUSRE34656E
OPPOSITIONUS5574026
SEARCHEP0582789
SEARCHGB935384

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHANDLER ET AL., J. NEUROIMMUNOL., (1997), vol. 72, pages 155 - 71-
DESCRIPTION- GREENWALD ET AL., BONE, (1998), vol. 22, pages 33 - 38-
DESCRIPTION- H. WISPLINGHOFF ET AL., CLIN. INFECT. DIS., (2004), vol. 39, pages 311 - 317-
DESCRIPTION- LIEDTKE ET AL., ANN. NEUROL., (1998), vol. 44, pages 35 - 46-
DESCRIPTION- LI ET AL., MOL. CARCILLOG., (1998), vol. 22, pages 84 - 89-
DESCRIPTION- RYAN ET AL., CURR. OP. RHEUMATOL., (1996), vol. 8, pages 238 - 247-
DESCRIPTION- S.E. DOWD ET AL., PLOS ONE, (2008), vol. 3, page E3326-
DESCRIPTION- STETLER-STEVENSON ET AL., ANNU. REV. CELL BIOL., (1993), vol. 9, pages 541 - 73-
DESCRIPTION- TRYGGVASON ET AL., BIOCHIM. BIOPHYS. ACTA, (1987), vol. 907, pages 191 - 217-
DESCRIPTION- VAN DER BOZERT ET AL., CANCER RES., (1988), vol. 48, pages 6686 - 6690-
OPPOSITION- DUNN C.J., "Outcomes review , Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections", Core Evidence, (20060000), vol. 3, pages 181 - 194, XP055505449-
OPPOSITION- EHLERS E., "Originalfragen und Kurzlehrbuch zur ''Organischen Chemie'' nach dem Gegenstandskatalog Pharmzie", Chemie II, (19920000), page 263, XP055505376-
OPPOSITION- SCHNEEMANN et al., "Angewandte Arzneimitteltherapie", Klinisch-Pharmazeutische Betreuung in Fallbeispielen, Berlin Heidelberg, (20010000), pages 673 - 709, XP055505436-
OPPOSITION- STEINHILBER D. et al., "Tetracycline", Medizinische Chemie , Targets und Arzneistoffe, (20050000), pages 536 - 538, XP055505253-
OPPOSITION- Textbook ''The Tetracyclines, Berlin Heidelberg , New York , Tokyo, (19850000), pages 214 - 223, XP055505394-
OPPOSITION- "TYGACIL (tigecycline) for injection", FDA U.S. Food & Drug, (20050000), XP055505404-
OPPOSITION- SUM P.-E. et al., "Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936", Bioorganic & Medicinal Chemistry Letters, (19990000), vol. 9, no. 10, pages 1459 - 1462, XP004164912
OPPOSITION- HAWKEY P. et al., "Tigecycline: in-vitro performance as a predictor of clinical efficacy", Clin Microbiol Infect, (20060000), vol. 13, no. 4, pages 354 - 362, XP055505460
SEARCH- SATO, F. ET AL, "Structure-activity relationship investigation of some new tetracyclines by electronic index methodology", LOS ALAMOS NATIONAL LABORATORY, PREPRINT ARCHIVE, QUANTITATIVE BIOLOGY 1-18, ARXIV:0708.2931V1 [Q-BIO.BM], 21 AUG 2007 CODEN: LANLCJ URL: HTTP://ARXIV.ORG/PS_CACHE/ARXIV/PDF/0708/0708.2931V1.PDF, (2007), XP002548287 [A] 1-19 * page 1, introduction: first two paragraphs * * page 10; table 4; compound 20 * * page 13, paragraph LAST *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents